Welcome to the ATBC Study Web Site
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study was a cancer prevention trial conducted by the U.S. National Cancer Institute (NCI) and the National Institute for Health and Welfare of Finland from 1985 to 1993. The purpose of the study was to determine whether certain vitamin supplements would prevent lung cancer and other cancers in a group of 29,133 male smokers in Finland. The 50- to 69-year-old participants took a pill daily for five to eight years that contained one of the following: 50 milligrams (mg) alpha-tocopherol (a form of vitamin E), as dl-alpha-tocopheryl acetate, 20 mg of beta-carotene (a precursor of vitamin A), as all-trans-beta-carotene, both, or a placebo (inactive pill that looked like the vitamin).
The participants stopped taking the vitamin supplements in April 1993. However, in order to evaluate the long-term effects of the vitamins on cancer incidence, and overall and cause-specific mortality, they were followed after the trial ended using data from the national registries in Finland. The researchers acquired additional data for cancer incidence and mortality related to specific causes through December 2008 and for total mortality through December 2010 (seventeen years beyond the end of the trial).
Text excerpted from the NCI Press Release: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study (http://www.cancer.gov/newscenter/pressreleases/ATBCfollowup)
For more information regarding study design and initial findings, download The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance (PDF) and the The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers (PDF).
To view the PDF files on this site, you will need Adobe Acrobat Reader.